Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.3 DKK | -2.01% | -4.56% | +6.74% |
04-23 | Transcript : Embla Medical hf., Q1 2024 Earnings Call, Apr 23, 2024 | |
04-23 | Embla Medical hf. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company benefits from high valuations in earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.74% | 1.83B | B+ | ||
-12.98% | 21.33B | B | ||
-5.28% | 16.56B | A | ||
+5.90% | 13.49B | B | ||
+9.80% | 10.01B | B- | ||
-13.54% | 2.16B | - | ||
+11.86% | 583M | - | ||
-.--% | 423M | - | - | |
+30.53% | 150M | - | ||
+26.62% | 96.11M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EMBLA Stock
- Ratings Embla Medical hf.